Stephen Keane is a seasoned life sciences executive with an extensive track record of success in corporate development, business development and financial transactions for emerging biopharmaceutical companies. He has been an officer of four publicly traded companies, raised over $400 million in equity capital in the last two decades and has helped generate more than $400 million in non-dilutive partner revenues to fund drug discovery programs.
Mr. Keane is currently CBO of Calidi Biotherapeutics. He is the co-founder of Staurus Pharma, served as SVP of Corporate Development of Leading Biosciences, President and CEO of Femta Pharmaceuticals and has held senior corporate development positions with Cosmo Pharmaceuticals S. A., Ambit Biosciences, Dendreon Corp., Corvas International, Epimmune Inc., SIBIA Neurosciences and Molecular Biosystems. He was responsible for negotiating significant alliances including licenses, distributions agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. He also served as the principal negotiator for Dendreon’s acquisition of Corvas International and Merck’s acquisition of SIBIA Neurosciences.
Mr. Keane received his Bachelor of Arts in English Literature from San Diego State University.